Table 2. Sensitivity, specificity, predictive value and odds ratio including 95% confidence interval for detecting CIN2+ (a) or CIN3 (b).

Initial diagnosis	CIN2+		Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	OR (95% CI)
a)	Positive	Negative
ASCUS
mRNA
Positive	59	131	96.7% (87.6–99.4)	12.7% (7.9–19.3)	31.0% (24.6–38.2)	90.5% (68.2–98.3)	4.3 (1.0–38.9)
Negative	2	19
CIN1
mRNA
Positive	44	81	97.8% (86.8–99.9)	5.8% (2.2–13.6)	35.2% (27.0–44.3)	83% (36.5–99.1)	2.7 (0.3–131)
Negative	1	5
	CIN3		Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	OR (95% CI)
b)	Positive	Negative*
ASCUS
mRNA
Positive	23	131	100% (82.2–100)	12.7% (8.0–19.3)	14.9% (9.9–21.8)	100% (79.1–100)	4.6 (0.7-INF)
Negative	0	19
CIN1
mRNA
Positive	20	81	100% (80.0–100)	5.8% (2.2–13.6)	19.8% (12.8–29.2)	100% (46.3–100)	1.6 (0.2-INF)
Negative	0	5

PPV, positive predictive value. NPV, negative predictive value. OR, odds ratio. INF, infinity.

* The reference group is women who did not develop CIN2+. Women who developed CIN2 are not included in this analysis.